Linked Life Data

7654480

Source:http://linkedlifedata.com/resource/pubmed/id/7654480

Statements in which the resource exists as a subject.
PredicateObject
rdf:type
lifeskim:mentions
pubmed:issue
6
pubmed:dateCreated
1995-9-29
pubmed:abstractText
1. Less than 5% of a dose of the conventional oral formulation of cyclosporin, Sandimmun, is absorbed in liver transplant recipients with external biliary drainage, necessitating intravenous administration of the drug and exposing the patient to increased risk of severe side-effects. 2. We compared the pharmacokinetics of the conventional oral formulation of cyclosporin with that of the new microemulsion formulation, Neoral, in eight liver transplant recipients with external biliary diversion. Patients were maintained on a continuous infusion of cyclosporin until steady-state conditions had been achieved. They were then given a test dose (10 mg kg-1) of either the conventional or microemulsion formulation (randomised order) followed by the same dose of the other formulation. Parent cyclosporin concentrations were measured in whole blood samples collected at timed intervals over the 24 h after the oral doses and pharmacokinetic parameters calculated. 3. The bioavailability of cyclosporin from the microemulsion formulation was, on average, 6.5-fold (95% C.I. 1.9 to 11.1-fold) greater than that of the conventional formulation, indicating the improved absorption characteristics of the new oral microemulsion formulation during external bile drainage. 4. A significant negative correlation was found between the external bile drainage volume and bioavailability of cyclosporin from the microemulsion formulation (r = -0.8; P = 0.016), suggesting that variability in cyclosporin absorption from the microemulsion formulation may still be at least partly attributable to bile- dependence.(ABSTRACT TRUNCATED AT 250 WORDS)
pubmed:commentsCorrections
http://linkedlifedata.com/resource/pubmed/commentcorrection/7654480-12959294, http://linkedlifedata.com/resource/pubmed/commentcorrection/7654480-1540489, http://linkedlifedata.com/resource/pubmed/commentcorrection/7654480-1578386, http://linkedlifedata.com/resource/pubmed/commentcorrection/7654480-1633069, http://linkedlifedata.com/resource/pubmed/commentcorrection/7654480-1676779, http://linkedlifedata.com/resource/pubmed/commentcorrection/7654480-1854763, http://linkedlifedata.com/resource/pubmed/commentcorrection/7654480-2799635, http://linkedlifedata.com/resource/pubmed/commentcorrection/7654480-2882342, http://linkedlifedata.com/resource/pubmed/commentcorrection/7654480-3044424, http://linkedlifedata.com/resource/pubmed/commentcorrection/7654480-3274312, http://linkedlifedata.com/resource/pubmed/commentcorrection/7654480-8094190
pubmed:language
eng
pubmed:journal
pubmed:citationSubset
IM
pubmed:chemical
pubmed:status
MEDLINE
pubmed:month
Jun
pubmed:issn
0306-5251
pubmed:author
pubmed:issnType
Print
pubmed:volume
39
pubmed:owner
NLM
pubmed:authorsComplete
Y
pubmed:pagination
627-31
pubmed:dateRevised
2009-11-18
pubmed:meshHeading
pubmed:year
1995
pubmed:articleTitle
Absorption of cyclosporin from conventional and new microemulsion oral formulations in liver transplant recipients with external biliary diversion.
pubmed:affiliation
Department of Clinical Biochemistry, Addenbrooke's Hospital, Cambridge.
pubmed:publicationType
Journal Article, Clinical Trial, Randomized Controlled Trial, Research Support, Non-U.S. Gov't